Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $17.75.

A number of equities analysts have recently commented on the stock. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective for the company. Canaccord Genuity Group restated a “buy” rating and set a $17.00 price target on shares of Atara Biotherapeutics in a research note on Tuesday, March 11th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in Atara Biotherapeutics during the 4th quarter valued at $332,000. Birchview Capital LP bought a new stake in shares of Atara Biotherapeutics during the fourth quarter worth $293,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the fourth quarter valued at $169,000. Vestal Point Capital LP raised its holdings in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares during the last quarter. Finally, Northern Trust Corp acquired a new position in Atara Biotherapeutics during the 4th quarter worth about $149,000. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Stock Up 3.9 %

Atara Biotherapeutics stock opened at $6.88 on Friday. The business has a 50 day moving average price of $7.59 and a two-hundred day moving average price of $9.63. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $20.81. The stock has a market cap of $40.31 million, a price-to-earnings ratio of -0.27 and a beta of 0.49.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, beating analysts’ consensus estimates of ($3.82) by $2.63. The firm had revenue of $32.75 million during the quarter, compared to analyst estimates of $20.58 million. On average, analysts expect that Atara Biotherapeutics will post -10.39 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.